Truist analyst Danielle Brill raised the firm’s price target on Neurocrine (NBIX) to $155 from $140 and keeps a Buy rating on the shares. The firm updated its Neurocrine model to reflect Q1 financial results, and adjusted its projections following management’s latest commentary on the outlook. Both Ingrezza and Crenessity sales exceeded Truist’s expectations for the quarter, and the firm believes the setup for Neurocrine is improving as base business outlook appears solid and it sees a positive risk/reward ahead of key pipeline readouts approaching in 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Evan Seigerman Maintains Hold on Neurocrine as Strong Commercial Execution Drives Price Target Increase to $144 Amid Strategic Uncertainty
- Neurocrine Biosciences: Hold Maintained as Analyst Lifts Price Target to $191 Amid Strong Ingrezza Demand and Pipeline Execution Risks
- Neurocrine Remains Top Pick on Durable Multi‑Year Growth Outlook; Buy Rating Reiterated with Unchanged $200 Price Target
- Neurocrine Biosciences Delivers Record Quarter, Eyes 2027
- Ami Fadia Reiterates Buy on NBIX After Strong 1Q26 Beat and Robust Ingrezza and Crenessity Demand